Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 5,300 Shares of Stock

Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $134.70, for a total transaction of $713,910.00. Following the transaction, the vice president now directly owns 24,908 shares in the company, valued at $3,355,107.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Thursday, December 28th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The stock was sold at an average price of $114.08, for a total transaction of $604,624.00.
  • On Thursday, December 28th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The stock was sold at an average price of $114.08, for a total transaction of $604,624.00.
  • On Wednesday, November 29th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The stock was sold at an average price of $116.45, for a total transaction of $617,185.00.

Shares of Edwards Lifesciences Corp (EW) traded down $0.07 during mid-day trading on Wednesday, reaching $134.25. 939,728 shares of the company traded hands, compared to its average volume of 1,362,758. Edwards Lifesciences Corp has a one year low of $89.20 and a one year high of $138.48. The stock has a market cap of $28,410.00, a P/E ratio of 49.72, a price-to-earnings-growth ratio of 1.98 and a beta of 0.63. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.15.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. The company had revenue of $888.50 million for the quarter, compared to the consensus estimate of $868.45 million. During the same period in the prior year, the firm posted $0.75 EPS. Edwards Lifesciences’s revenue for the quarter was up 15.7% on a year-over-year basis. analysts anticipate that Edwards Lifesciences Corp will post 4.49 EPS for the current year.

Edwards Lifesciences announced that its Board of Directors has approved a stock buyback plan on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s board believes its stock is undervalued.

A number of analysts have recently weighed in on the stock. JMP Securities upped their target price on shares of Edwards Lifesciences from $135.00 to $140.00 and gave the stock a “market outperform” rating in a research report on Friday, February 2nd. SunTrust Banks reaffirmed a “buy” rating and issued a $150.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, January 31st. Guggenheim reaffirmed a “buy” rating and issued a $162.00 target price on shares of Edwards Lifesciences in a research report on Friday, February 2nd. Barclays reduced their target price on shares of Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 25th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $137.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, November 29th. Three investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Edwards Lifesciences has an average rating of “Buy” and a consensus target price of $141.15.

Hedge funds have recently made changes to their positions in the stock. Cerebellum GP LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at about $128,000. Resources Investment Advisors Inc. grew its position in Edwards Lifesciences by 66.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 465 shares during the last quarter. Exane Derivatives grew its position in Edwards Lifesciences by 381.3% during the 4th quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 961 shares during the last quarter. Dupont Capital Management Corp bought a new position in Edwards Lifesciences during the 3rd quarter valued at about $142,000. Finally, Lake Street Advisors Group LLC bought a new position in Edwards Lifesciences during the 4th quarter valued at about $201,000. 81.23% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 5,300 Shares of Stock” was published by Week Herald and is owned by of Week Herald. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://weekherald.com/2018/02/21/insider-selling-edwards-lifesciences-corp-ew-vp-sells-5300-shares-of-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply